Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dunn

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
International Journal of Environmental Research and Public Health|January 16, 2020
Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and WalesT Charles Witzel, Peter Weatherburn, Adam Bourne, et al.
Antiviral Therapy|February 17, 2007
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green, Diana M Gibb, Alexandra Compagnucci, et al.
AIDS (London, England)|April 14, 2010
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children, K Boyd, David T Dunn, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
International Journal of Environmental Research and Public Health|January 16, 2020
Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and WalesT Charles Witzel, Peter Weatherburn, Adam Bourne, et al.
Antiviral Therapy|February 17, 2007
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green, Diana M Gibb, Alexandra Compagnucci, et al.
AIDS (London, England)|April 14, 2010
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children, K Boyd, David T Dunn, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Pageof 8